Blisibimod - Anthera Pharmaceuticals

Drug Profile

Blisibimod - Anthera Pharmaceuticals

Alternative Names: A-623; AMG-623; Blisibimod

Latest Information Update: 02 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen
  • Developer Anthera Pharmaceuticals
  • Class Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action B cell activating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - IgA nephropathy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Systemic lupus erythematosus
  • Phase II IgA nephropathy
  • Discontinued Chronic lymphocytic leukaemia

Most Recent Events

  • 02 May 2018 Anthera Pharmaceuticals has patent protection for blisibimod in USA and Europe
  • 28 Aug 2017 Updated efficacy and adverse events data from the phase II BRIGHT-SC trial in IgA nephropathy released by Anthera Pharmaceuticals
  • 28 Aug 2017 Anthera Pharmaceuticals completes the phase II BRIGHT-SC trial in IgA nephropathy (Combination therapy, Treatment-experienced) in Hong Kong, South Korea, Malaysia, Philippines, Singapore, Taiwan, Czech Republic, Germany, United Kingdom, Italy, Hungary, Sweden, Spain and Thailand (EudraCT2014-001365-26) (NCT02062684)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top